XTL Biopharmaceuticals

Historical price data

XTL Biopharmaceuticals Ltd. is a publicly traded, clinical-stage company with a mission to address unmet needs in autoimmune diseases through the strategic acquisition and development of late-stage drug candidates. Its primary achievement is the advancement of its lead peptide asset, hCDR1, through multiple clinical trials for systemic lupus erythematosus and lupus nephritis. The company's strategy centers on a lean, capital-efficient model focused on de-risking and enhancing the value of specific assets for potential partnerships or strategic exits. XTL operates from its headquarters in Rehovot, Israel, leveraging its expertise in asset selection and clinical development within its focused therapeutic niche.

The company's core platform is its business development and asset selection expertise for in-licensing late-stage candidates. Its lead scientific asset, hCDR1, is based on a peptide immunomodulation platform designed to target specific pathogenic pathways in autoimmune disease.

XTL competes in the crowded SLE/LN market against established biologics (e.g., belimumab, anifrolumab, voclosporin) and a robust pipeline of novel mechanisms. Its differentiation hinges on hCDR1's unique peptide-based, targeted immunomodulation and a potential superior safety profile, but it lacks the commercial scale of its rivals.